Shariat Shahrokh F, Svatek Robert S, Kabbani Wareef, Walz Jochen, Lotan Yair, Karakiewicz Pierre I, Roehrborn Claus G
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.
BJU Int. 2008 Jan;101(2):232-7. doi: 10.1111/j.1464-410X.2007.07181.x. Epub 2007 Sep 13.
To investigate the association of syndecan-1 expression with pathological features and disease progression in patients treated with radical prostatectomy (RP) as syndecan-1 plays a role in the regulation of cell proliferation, migration, and differentiation and its expression is altered in various malignancies.
Syndecan-1 immunostaining was performed on a tissue microarray containing cores from 232 consecutive patients treated with RP and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. Patients were categorized as having features of aggressive progression if they had evidence of metastases, an after progression prostate-specific antigen (PSA) doubling time of < 10 months, and/or failure to respond to local salvage radiation therapy. Expression was defined as > or = 10% cells staining for syndecan-1.
Syndecan-1 was expressed in 86 patients (37.1%). Expression of syndecan-1 was associated with higher PSA levels (P = 0.004), higher pathological Gleason sum (P = 0.027) and lymph nodes metastases (P = 0.027). Patients with syndecan-1 expression were at significantly greater risk of PSA-progression after surgery (P = 0.034) in univariate but not in multivariate analysis. Patients with features of aggressive progression (n = 22) were more likely to express syndecan-1 than those with features of nonaggressive progression (63.6% vs 36.4%, P = 0.010). Patients with syndecan-1 expression were at significantly greater risk of aggressive progression after surgery (P = 0.005) in univariate but not in multivariate analysis.
Expression of syndecan-1 was associated with established features of biologically aggressive prostate cancer and PSA-progression in univariate analysis. These findings suggest a role for syndecan-1 in prostate carcinogenesis and progression.
由于Syndecan-1在细胞增殖、迁移和分化的调控中发挥作用，且其表达在多种恶性肿瘤中发生改变，因此研究接受根治性前列腺切除术（RP）的患者中Syndecan-1表达与病理特征及疾病进展的相关性。
对包含232例因临床局限性前列腺癌接受RP及双侧淋巴结清扫术的连续患者的组织芯的组织微阵列进行Syndecan-1免疫染色。如果患者有转移证据、进展后前列腺特异性抗原（PSA）倍增时间<10个月和/或对局部挽救性放射治疗无反应，则被分类为具有侵袭性进展特征。表达定义为Syndecan-1染色的细胞≥10%。
86例患者（37.1%）表达Syndecan-1。Syndecan-1的表达与较高的PSA水平（P = 0.004）、较高的病理Gleason评分（P = 0.027）和淋巴结转移（P = 0.027）相关。在单变量分析中，Syndecan-1表达的患者术后PSA进展风险显著更高（P = 0.034），但在多变量分析中并非如此。具有侵袭性进展特征的患者（n = 22）比无侵袭性进展特征的患者更可能表达Syndecan-1（63.6%对36.4%，P = 0.010）。在单变量分析中，Syndecan-1表达的患者术后侵袭性进展风险显著更高（P = 0.005），但在多变量分析中并非如此。
在单变量分析中，Syndecan-1的表达与具有生物学侵袭性前列腺癌的既定特征及PSA进展相关。这些发现提示Syndecan-1在前列腺癌发生和进展中起作用。
